Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 1693-1695, 2004. First published July 20, 2004; 10.1373/clinchem.2004.034165
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.034165v1
50/9/1693    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Görgens, H.
Right arrow Articles by Schackert, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Görgens, H.
Right arrow Articles by Schackert, H. K.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2004;50:1693-1695.)
© 2004 American Association for Clinical Chemistry, Inc.

Technical Briefs

One-Step Analysis of Ten Functional Haplotype Combinations of the Basic RET Promoter with a LightCycler Assay

Heike Görgens1,1, Guido Fitze2,1, Dietmar Roesner2 and Hans K. Schackert1,a

Departments of1 Surgical Research and2 Pediatric Surgery, Universitätsklinikum Carl Gustav Carus, Dresden University of Technology, Dresden, Germany;

aaddress correspondence to this author at: Department of Surgical Research, Universitätsklinikum Carl Gustav Carus, Dresden University of Technology, Fetscherstrasse 74, D-01307 Dresden, Germany; fax 49-351-458-4350, e-mail schacker@rcs.urz.tu-dresden.de

The first 20% of the full text of this article appears below.

The RET protooncogene is expressed in human tissues of neural crest origin and has been recognized as a susceptibility gene for several autosomal inherited diseases, such as the multiple endocrine neoplasia type 2 syndromes, familial medullary thyroid carcinoma, and Hirschsprung disease (HSCR) (1). In addition to RET germline mutations, associations of several polymorphisms of the RET protooncogene with HSCR have been reported previously, and in particular, the c.135A RET variant has been shown to be strongly associated with the HSCR phenotype (2)(3). In addition to the mutation-independent effect of the c.135A allele in the etiology of HSCR, we have been reporting a HSCR-phenotype-modifying effect of the RET c.135G>A alleles (rs1800858) that result from a within-gene interaction in patients harboring RET germline mutations (4).

We have demonstrated (5) that variants of two RET promoter polymorphisms, –5G>A (rs10900296) and –1C>A (rs10900297), from the transcription start site are associated with HSCR and that the –5G>A polymorphism is in strong linkage disequilibrium with the c.135G>A polymorphism. Because the promoter haplotype –5/–1AC associated with HSCR has a significantly lower activity in an in vitro dual-luciferase expression assay than do those haplotypes identified in the majority of healthy controls, we thus provided evidence that the c.135G>A polymorphism is a marker for a functional variant in the RET promoter (5). Our findings support the concept that the involvement of both . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.